Viridian Therapeutics, Inc. (VRDN) experienced a significant pre-market plunge of 6.67% on Wednesday, as investor sentiment turned negative following the release of detailed financial analysis highlighting the company's substantial losses and challenging path to profitability.

The sharp decline appears to be a reaction to recent analysis showing Viridian Therapeutics reported trailing losses of approximately US$281.9 million over the past year, with quarterly losses ranging as high as US$101.1 million. The company's revenue has shown extreme volatility, swinging from as low as US$0.07 million to US$70.57 million in different quarters, raising questions about the sustainability of its financial performance. Additionally, the stock trades at a rich price-to-sales ratio of 27.3x compared to industry peers, amplifying concerns about valuation given the company's ongoing losses and shareholder dilution risks.

Investors are particularly focused on the tension between Viridian's current financial performance and optimistic forecasts suggesting the company could reach profitability within three years. The pre-market selling pressure reflects growing skepticism about whether the company can successfully navigate from its current loss-making position to sustainable profitability given the scale of its financial challenges.